Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease

被引:58
作者
Tyndall, JDA
Reid, RC
Tyssen, DP
Jardine, DK
Todd, B
Passmore, M
March, DR
Pattenden, LK
Bergman, DA
Alewood, D
Hu, SH
Alewood, PF
Birch, CJ [1 ]
Martin, JL
Fairlie, DP
机构
[1] Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia
[2] Victorian Infect Dis Ref Lab, Carlton, Vic 3053, Australia
[3] Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Herston, Qld 4029, Australia
关键词
D O I
10.1021/jm000013n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Three new peptidomimetics (1-3) have been developed with highly stable and conformationally constrained macrocyclic components that replace tripeptide segments of protease substrates. Each compound inhibits both HIV-1 protease and viral replication (HIV-I, HIV-2) at nanomolar concentrations without cytotoxicity to uninfected cells below 10 mu M. Their activities against HIV-1 protease (K-i 1.7 nM (1), 0.6 nM (2), 0.3 nM (3)) are 1-2 orders of magnitude greater than their antiviral potencies against HIV-1-infected primary peripheral blood mononuclear cells (IC50 45 nM (1), 56 nM (2), 95 nM (3)) or HIV-1-infected MT2 cells (IC50 90 nM (1), 60 nM (2)), suggesting suboptimal cellular uptake. However their antiviral potencies are similar to those of indinavir and amprenavir under identical conditions. There were significant differences in their capacities to inhibit the replication of HIV-1 and HIV-2 in infected MT2 cells, 1 being ineffective against HIV-2 while 2 was equally effective against both virus types. Evidence is presented that 1 and 2 inhibit cleavage of the HIV-1 structural protein precursor Pr55(gag) to p24 in virions derived from chronically infected cells, consistent with inhibition of the viral protease in cells. Crystal structures refined to 1.75 Angstrom (1) and 1.85 Angstrom (2) for two of the macrocyclic inhibitors bound to HIV-1 protease establish structural mimicry of the tripeptides that the cycles were designed to imitate. Structural comparisons between protease-bound macrocyclic inhibitors, VX478 (amprenavir), and L-735,524 (indinavir) show that their common acyclic components share the same space in the active site of the enzyme and make identical interactions with enzyme residues. This substrate-mimicking minimalist approach to drug design could have benefits in the context of viral resistance, since mutations which induce inhibitor resistance may also be those which prevent substrate processing.
引用
收藏
页码:3495 / 3504
页数:10
相关论文
共 44 条
[1]   REGIOSELECTIVE STRUCTURAL AND FUNCTIONAL MIMICRY OF PEPTIDES - DESIGN OF HYDROLYTICALLY-STABLE CYCLIC PEPTIDOMIMETIC INHIBITORS OF HIV-1 PROTEASE [J].
ABBENANTE, G ;
MARCH, DR ;
BERGMAN, DA ;
HUNT, PA ;
GARNHAM, B ;
DANCER, RJ ;
MARTIN, JL ;
FAIRLIE, DP .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (41) :10220-10226
[2]   KINETIC-PROPERTIES OF HIV-1 PROTEASE PRODUCED BY TOTAL CHEMICAL SYNTHESIS WITH CYSTEINE RESIDUES REPLACED BY ISOSTERIC L-ALPHA-AMINO-N-BUTYRIC ACID [J].
BERGMAN, DA ;
ALEWOOD, D ;
ALEWOOD, PF ;
ANDREWS, JL ;
BRINKWORTH, RI ;
ENGLEBRETSEN, DR ;
KENT, SBH .
LETTERS IN PEPTIDE SCIENCE, 1995, 2 (02) :99-107
[3]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[4]   ASSESSMENT OF PHASE ACCURACY BY CROSS VALIDATION - THE FREE R-VALUE - METHODS AND APPLICATIONS [J].
BRUNGER, AT .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1993, 49 :24-36
[5]  
Brunger AT, 1992, XPLOR VERSION 3 1 MA
[6]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 2-LTR CIRCLES RESIDE IN A NUCLEOPROTEIN COMPLEX WHICH IS DIFFERENT FROM THE PREINTEGRATION COMPLEX [J].
BUKRINSKY, M ;
SHAROVA, N ;
STEVENSON, M .
JOURNAL OF VIROLOGY, 1993, 67 (11) :6863-6865
[7]  
CHEN ZG, 1994, J BIOL CHEM, V269, P26344
[8]   IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS [J].
CONDRA, JH ;
SCHLEIF, WA ;
BLAHY, OM ;
GABRYELSKI, LJ ;
GRAHAM, DJ ;
QUINTERO, JC ;
RHODES, A ;
ROBBINS, HL ;
ROTH, E ;
SHIVAPRAKASH, M ;
TITUS, D ;
YANG, T ;
TEPPLER, H ;
SQUIRES, KE ;
DEUTSCH, PJ ;
EMINI, EA .
NATURE, 1995, 374 (6522) :569-571
[9]  
Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X
[10]   ACCURATE BOND AND ANGLE PARAMETERS FOR X-RAY PROTEIN-STRUCTURE REFINEMENT [J].
ENGH, RA ;
HUBER, R .
ACTA CRYSTALLOGRAPHICA SECTION A, 1991, 47 :392-400